• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Rebecca Chin, PhD


  • Chin YM, Yuan X, Balk SP, Toker A.Pten-deficient tumors depend on akt2 for maintenance and survival.Cancer Discovery. 2014 May 16.
  • Toker A, Chin YR.Akt-ing up on SRPK1: oncogene or tumor suppressor?.Mol Cell. 2014 May 8;54(3):329-30.
  • Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A.Targeting Akt3 signaling in triple-negative breast cancer.Cancer Res. 2014 Feb 1;74(3):964-73.
  • Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, Kocher ON, Brown LF, Toker A, Prendergast GC, Benjamin LE.RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.Cancer Res. 2012 Nov 7.
  • Inuzuka H, Gao D, Finley LW, Yang W, Wan L, Fukushima H, Chin YR, Zhai B, Shaik S, Lau AW, Wang Z, Gygi SP, Nakayama K, Teruya-Feldstein J, Toker A, Haigis MC, Pandolfi PP, Wei W.Acetylation-dependent regulation of Skp2 function.Cell. 2012 Jul 6;150(1):179-93.
  • Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, Wan L, Zhai B, Chin YR, Shaik S, Lyssiotis CA, Gygi SP, Toker A, Cantley LC, Asara JM, Harper JW, Wei W.mTOR drives its own activation via SCF(╬▓TrCP)-dependent degradation of the mTOR inhibitor DEPTOR.Mol Cell. 2011 Oct 21;44(2):290-303.
  • Yiu GK, Kaunisto A, Chin YR, Toker A.NFAT Promotes Carcinoma Invasive Migration Through Glypican-6.Biochem J. 2011 Aug 26.
  • Chin YR, Toker A.Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin.Cell Adh Migr.;5(3):211-4.
  • Chin YR, Toker A.Akt2 regulates expression of the actin-bundling protein palladin.FEBS Lett. 2010 Dec 1;584(23):4769-74.
  • Chin YR, Toker A.The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.Mol Cell. 2010 May 14;38(3):333-44.
  • Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R.3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.Cancer Res. 2009 Aug 1;69(15):6299-306.
  • Gao D,Inuzuka H,Tseng A,Chin RY,Toker A,Wei W.Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.Nat Cell Biol. 2009 Apr;11(4):397-408.
  • Yoeli-Lerner M,Chin YR,Hansen CK,Toker A.Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor.Mol Cancer Res. 2009 Mar;7(3):425-32.
  • Chin YR,Toker A.Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer.Cell Signal. 2009 Apr;21(4):470-6.
  • Chin YR, Horwitz MS.Adenovirus RID complex enhances degradation of internalized tumour necrosis factor receptor 1 without affecting its rate of endocytosis.J Gen Virol. 2006 Nov;87(Pt 11):3161-7.
  • Chin YR, Horwitz MS.Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex.J Virol. 2005 Nov;79(21):13606-17.
  • Fessler SP, Chin YR, Horwitz MS.Inhibition of tumor necrosis factor (TNF) signal transduction by the adenovirus group C RID complex involves downregulation of surface levels of TNF receptor 1.J Virol. 2004 Dec;78(23):13113-21.
  • Zho S, Chiang D, Chin R, Kestell P, Paxton JW.High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 5;767(1):19-26.